Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 5542 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 26 27 28 ... 54 55 56  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Cunesoft–Bavaria (govt): investment, 201410 financing round with HTGF + Bayern Kapital 2014-10-28
Cunesoft–High-Tech Gründerfonds: investment, 201410 financing round with HTGF + Bayern Kapital 2014-10-28
Cunesoft–SEVERAL: investment, 201410 financing round with HTGF + Bayern Kapital 2014-10-28
Imevax–BioMedPartners: investment, 201410 financing round Series A totalling €7.5m incl co-lead investor BioMedInvest-II LP fund 2014-10-28
Imevax–EMBL: investment, 201410 financing round Series A totalling €7.5m incl co-lead investor EMBL Ventures 2014-10-28
Imevax–MC Services: public relations, 201410 service existent by MC Services AG 2014-10-28
Imevax–SEVERAL: investment, 201410 financing round Series A €7.5m led by Wellington Partners 2014-10-28
Imevax–Strüngmann Group: investment, 201410 financing round Series A totalling €7.5m incl co-lead investor Santo Venture Capital 2014-10-28
Imevax–Wellington Partners: investment, 201410 financing round Series A totalling €7.5m incl lead investor Wellington Partners 2014-10-28
National Cardiovascular Partners–Fresenius: investment, 201410 acquisition €na of NCP by Fresenius Medical Care 2014-10-22
YES Pharma Services–Auctus Capital: investment, 201410 acquisition of majority share by funds advised by Auctus Capital Partners AG 2014-10-22
VBC-Biotech–Eurofins: investment, 201410 acquisition merger establishing Eurofins Genomics AT GmbH taking over VBC services 2014-10-21
Weizmann Institute–XL-protein: PASylation technology, 201410– Yeda acquires ww excl marketing + outlicensing rights to PAS-YNSa8 dev by XL + Weizmann 2014-10-21
Univ Lausanne–Thermo Fisher: mass spectrometer, 201410 supply existent Bertrand Rochat early access user of Q Exactive Focus LC-MS/MS system 2014-10-20
Epigenomics–BioChain: investment, 201410 acquisition €4.2m 1.35m new shares €3.08/share by BioChain Institute Inc 2014-10-16
Roche–NewLink Genetics: cancer drugs, 201410– collab drug discovery IDO/TDO inhibitors with Genentech 2014-10-16
MorphoSys–Lanthio Pharma: LanthioPep technology, 201410 acquisition €na technology + all related IP by MorphoSys 2014-10-15
Bicylce Therapeutics–SEVERAL: investment, 201410 financing round £20m incl Atlas Venture + Novartis VF + SR One + SVLS + Astellas Venture 2014-10-14
Raze Therapeutics–SEVERAL: investment, 201410 financing round Series A $24m from Atlas Venture + MPM + MS Ventures + PIF + Astellas + Novartis 2014-10-14
Rigontec–Boehringer: investment, 201410 financing round Series A 1st closing totalling €9.45m co-led by Wellington Partners + BIVF 2014-10-14
Rigontec–High-Tech Gründerfonds: investment, 201410 financing round Series A 1st closing totalling €9.45m incl co-investor HTGF 2014-10-14
Rigontec–Huntsworth: public relations, 201410 service existent by Citigate Dewe Rogerson 2014-10-14
Rigontec–North Rhine-Westphalia (govt): investment, 201410 financing round Series A 1st closing totalling €9.45m incl co-investor NRW.Bank 2014-10-14
Rigontec–SEVERAL: investment, 201410 financing round Series A 1st closing €9.45m co-led by Wellington Partners + BIVF 2014-10-14
Rigontec–Wellington Partners: investment, 201410 financing round Series A 1st closing totalling €9.45m co-led by Wellington Partners + BIVF 2014-10-14
Probiodrug–Hume Brophy: public relations, 201410 service existent by Hume Brophy 2014-10-10
4 Animals AlsterScience–Hamburg (govt): investment, 201410 seed financing round from HTGF + Innovationsstarter Fonds + Business Angel 2014-10-09
4 Animals AlsterScience–High-Tech Gründerfonds: investment, 201410 seed financing round from HTGF + Innovationsstarter Fonds + Business Angel 2014-10-09
4 Animals AlsterScience–SEVERAL: investment, 201410 seed financing round from HTGF + Innovationsstarter Fonds + Business Angel 2014-10-09
Roche–AbVitro: PETE technology, 201410 acquisition €na of primer extension based target enrichment technology by Roche 2014-10-09
Mimetas–SEVERAL: investment, 201510 financing round $5.2m from ZIF + PPM Oost et al 2014-10-08
Horizon Discovery–Haplogen: cell lines, 201410– distribution ww of cell line engineering services + Haplogen human knockout cell lines by Horizon 2014-10-06
TVM–SEVERAL: investment, 201410 final closing of $201.6m fund TVM Life Science Ventures VII incl Teralys Capital + Lilly 2014-10-06
Cell Marque–Sigma-Aldrich: investment, 201410–201411 acquisition €na of Cell Marque Corp by Sigma-Aldrich 2014-10-03
Forbion–SEVERAL: investment, 201410 first close €92m of FCF III fund with target size of €150–200m 2014-10-03
Danaher–Illumina: OneOmics cloud computing environment, 201410– collab product integration Illumina NGS w AB Sciex SWATH proteomics on BaseSpace 2014-10-02
Abionic–SEVERAL: investment, 201410 financing round Series B CHF3.8m 2014-10-01
Analytik Jena–PERSON: investment, 201410 DIVESTMENT Klaus Berka to sell his shares to Endress+Hauser (Deutschland) GmbH & Co KG 2014-10-01
Analytik Jena–Thuringia (govt): investment, 201410 DIVESTMENT TIB to sell shares in AJ to Endress+ Hauser (Deutschland) AG & Co KG 2014-10-01
Bayer–Belchim Crop Protection: fungicide, 201410– acquisition sole European distribution rights €na for biofungicide Contans WG by Bayer CropScience 2014-10-01
Bayer–Univ Kyoto: drug discovery, 201410–201609 collab 2y to jointly identify drug candidates of KU-SACI + Bayer Open Innovation Center Japan 2014-10-01
Curasan–SEVERAL: investment, 201410 capital increase w subscription rights €1.5m 2014-10-01
Imevax–Germany (govt): grant, 201410 GO-Bio Phase II grant €5.9m from BMBF 2014-10-01
Merck (US)–Bayer: OTC drugs, 201410 acquisition $14.2b in cash of Merck’s consumer care business incl Claritin by Bayer 2014-10-01
Merck (US)–Bayer: sGC modulators, 201410– collab strategic alliance ww co-developm + co-commercialisation $1b upfront + $1.1b milestones 2014-10-01
Multi Channel Systems MCS–Harvard Bioscience: investment, 201410 acquisition €7.5m in cash by Harvard Bioscience 2014-10-01
SAW Instruments–NanoTemper: investment, 201410 acquisition by NanoTemper Technologies GmbH 2014-10-01
Singapore (govt)–Bruker Corp: imaging technology, 201410 collab establishment of joint SBIC-Bruker Preclinical Imaging (PCI) Center 2014-10-01
Life Sciences Partners–SEVERAL: investment, 201409 launch €80m LSP 5 fund with target size of €150m 2014-09-30
Metrohm–Ecknauer & Schoch: public relations, 201409 service existent 2014-09-29
Shimadzu–m/e Brand Communication: public relations, 201409 service existent 2014-09-29
Probiodrug–SEVERAL: investment, 201409–201410 IPO €23.2m at Euronext Amsterdam 2014-09-25
Fuchs Petrolub–BRAIN: lubricant, 201409– collab development of lubricants produced from renewable raw materials 2014-09-24
Molecular Partners–SEVERAL: investment, 201409–201412 IPO CHF106.2m at SIX Swiss Exchange 2014-09-23
Sigma-Aldrich–Merck (DE): investment, 201409–201511 acquisition $17b in cash 2014-09-22
Analytik Jena–Endress+Hauser: investment, 201409–201410 acquisition of addit 27.56% from Klaus Berka + TIB rasing share to 82.22% 2014-09-18
Boehringer–CureVac: RNActive vaccine, 20140901– collab developm + excl ww license for CV9202 €35m upfront + €430m milestones + royalties 2014-09-18
Cardiorentis–HealthCare Royalty Partners: financing, 201409 financing agreement €45m with undislosed features 2014-09-17
OSE Pharma–SEVERAL: investment, 201409–201503 IPO €21.1m at Euronext Paris 2014-09-17
Merck (DE)–Lupin: pharmaceuticals, 201409– strategic alliance €na developm + dossiers + supply by Lupin + marketing Merck Serono in emerging markets 2014-09-16
MorphoSys–Germany (govt): grant, 201409– BMBF grant up to €1m to develop Ylanthia antibodies against two undisclosed GPCR targets 2014-09-15
Nobel Biocare–Danaher: investment, 201409–201412 public cash tender offer CHF17/share w total value of $2.2b incl debt assumed + net of cash acquired 2014-09-15
SensoQuest–Eppendorf: thermal cycler, 201409– license covering gradient technology for thermal cyclers to SensoQuest GmbH 2014-09-15
Abbott–Biocartis: molecular diagnostics, 201409 collab existent development of diagnostic tests with Abbott Molecular 2014-09-12
Boehringer–Minapharm: rec protein production technology, 201409 license existent from ProBioGen 2014-09-09
Novartis–Minapharm: rec protein production technology, 201409 license existent from ProBioGen 2014-09-09
Vexim–LifeSci: public relations, 201409 service existent by LifeSci Advisors 2014-09-08
Zürcher Kantonalbank–Bellevue: investment, 201409– acquisition 100% of Adamant Biomedical Investments AG from ZKB 2014-09-05
Biocartis–SEVERAL: investment, 201409 financing round €64.5m from JnJ + Hitachi + PMV Tina Fund + family offices 2014-09-04
MyCartis–SEVERAL: investment, 201409 1st financing round €15m from RMM + Valiance + Biover II 2014-09-04
Pronota–Biocartis: investment, 201409 merger of Pronota with spun-out Swiss Evaluation business of Biocartis to form MyCartis 2014-09-04
4SC–Yorkville Group: credit, 201409 second tranche €500k convertible notes under up to €15m agreem from 2/14 w YA Global Master SPV Ltd 2014-09-03
Nabriva–Hume Brophy: public relations, 201409 service existent by Hume Brophy 2014-09-03
Affimed–Perceptive Advisors: credit, 201409– loan agreem over €10.5m 2014-09-02
Affimed–SEVERAL: investment, 201409 financing round Series E €11.7m led by existing investors 2014-09-02
BeiGene–Boehringer: biopharmaceuticals, 201409– strategic supply + manufacturing agreem for biopharmaceuticals using mammalian cell culture technology 2014-09-02
Merck (DE)–S-Target Therapeutics: S-TIR technology, 201409– license excl ww €na to Allergopharma to develop antiallergics 2014-09-02
Bayer–MetaSysX: metabolomic services, 201409–201708 supply services to Bayer CropScience to improve agricultural productivity 2014-09-01
Berlin Cures–Helmholtz: investment, 201409 Ascenion acquires shares at time of spin-off from Charité + MDC in return for services 2014-09-01
Berlin Cures–Minverva Partners: investment, 201409 seed investment at time of spin-off from Charité + MDC from Minerva Partners AG 2014-09-01
CHDI–Evotec: drug discovery services, 201409–201708 collab service extension CDHI funding up to 52 full-time scientists for Huntington’s disease drugs 2014-09-01
Corgenix Medical–Orgentec: investment, 201409–201503 acquisition of Corgenix for $16m in cash by Orgentec Diagnostika 2014-09-01
Ipsen–MHH: rec botulinum neurotoxin, 201409– collab r+d with Thomas Binz at Institute for Physiological Chemistry at MHH 2014-09-01
Univ Hamburg–Bruker Corp: MPI system, 201409 supply installation of 1st commercial MPI PreClinical system at UKE 2014-09-01
BASF–Cenix BioScience: biomarker discovery + validation, 201408– supply service €na research framework agreement with Metanomics Health 2014-08-26
Recipe–Tecan: automated liquid handling, 201408– collab co-marketing of ClinMass LC-MSMS Complete Kits with Freedom EVO platform 2014-08-26
Covagen–JnJ: investment, 201408 acquisition €na by Cilag GmbH International 2014-08-25
Eppendorf–Wallinger Ricker Schlotter Tostmann: legal services, 201408 Eppendorf is client of WRST with regard to gradient PCR patent litigation 2014-08-25
SensoQuest–Rehberg Hüppe: legal services, 201408 SensoQuest is client of RHP with regard to gradient PCR patent litigation 2014-08-25
InterMune–Roche: investment, 201408– acquisition $8.3b in cash 2014-08-24
Bruker Corp–F-DGSi: gas generator, 201408 supply + collab existent resale of F-DGSi gas generators by Bruker with Bruker instruments 2014-08-22
Gamida Cell–Novartis: investment, 201408 acquisiton 14% equity share for $35m by Novartis Pharma AG plus option to fully acquire Gamida Cell 2014-08-19
MorphoSys–Emergent BioSolutions: antibody cancer drug, 201408– collab developm + commercialisation rights or ES414 outside North America for MorphoSys 2014-08-19
Bruker Corp–CMS: legal services, 201408 service legal advice by CMS Hasche Sigle on acqu of Bruker’s ICP-MS business by Analytik Jena 2014-08-14
Lentigen–Miltenyi Biotec: investment, 201408 acquisition lentiviral manufacturing business + assets continuing as Miltenyi sub Lentigen Technology Inc 2014-08-14
Miltenyi Biotec–Scott Partnership: public relations, 201308 service existent by Phoenix MarCom 2014-08-14
Bruker Corp–Analytik Jena: investment, 201407–201409 acquisition €na of ICP-MS business from Bruker by AJ 2014-08-13
RayBiotech–Scienion: print/spotting technology, 201408– distribution €na of Scienion products in China by RayBiotech Inc 2014-08-13
Seventh Sense Biosystems–Novartis: investment, 201408 financing round Series B totalling $16m incl new investor Novartis 2014-08-13
Seventh Sense Biosystems–SEVERAL: investment, 201408 financing round Series B $16m from Siemens + Novartis + LabCorp + Flagship + Polaris 2014-08-13
next pagenext page 1 2 3 ... 26 27 28 ... 54 55 56  next pagenext page



Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica iito 600x60px

» top